Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 4/20 | 0.57 |
| ▸ | MDM4 | O15151 | 2/20 | 0.53 |
| ▸ | TP53 | P04637 | 2/20 | 0.53 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29423514 | 1.00 | CASP3 (0.57) | CASP3MDM4TP53MDM2KMT2A | |
| SCHEMBL7423417 | 1.00 | CASP3 (0.57) | CASP3MDM4TP53MDM2KMT2A | |
| SCHEMBL2313063 | 1.00 | CASP3 (0.57) | CASP3MDM4TP53MDM2KMT2A | |
| SCHEMBL13163967 | 1.00 | CASP3 (0.57) | CASP3MDM4TP53MDM2KMT2A | |
| SCHEMBL29361981 | 1.00 | CASP3 (0.57) | CASP3MDM4TP53MDM2KMT2A | |
| SCHEMBL29511158 | 0.91 | CASP3 (0.52) | CASP3MDM4TP53MDM2KMT2A | |
| SCHEMBL8350965 | 0.91 | CASP3 (0.52) | CASP3MDM4TP53MDM2KMT2A | |
| SCHEMBL13636676 | 0.91 | MDM4 (0.51) | CASP3MDM4TP53MDM2KMT2A | |
| SCHEMBL18358965 | 0.91 | CASP3 (0.55) | CASP3MDM4TP53MDM2KMT2A | |
| SCHEMBL29477062 | 0.90 | MDM4 (0.55) | CASP3MDM4TP53MDM2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 139 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120137003-A | Method for chemically synthesizing glycosylated insulin | 中国医学科学院药物研究所 | 2025-06-13 | — | — | CN | claimed |
| CN-120118155-A | PD-L1 targeted polypeptide positron probe and preparation method and application thereof | 南方医科大学南方医院 | 2025-06-10 | — | — | CN | claimed |
| CN-118994308-A | Industrial preparation method of small peptide for promoting wound healing | 广州优然生物科技有限公司 | 2024-11-22 | — | — | CN | claimed |
| CN-112638934-B | Solution phase Path for WNT hexapeptide | 温特研究公司 | 2024-06-11 | — | — | CN | claimed |
| US-11970551-B2 | Solution phase routes for WNT hexapeptides | WNTRESEARCH AB (SE) | 2024-04-30 | — | — | US | claimed |
| CN-117865829-A | Preparation method of N- (9-fluorenylmethoxycarbonyl) -aspartic acid-1-tert-butyl ester | 吉尔生化（上海）有限公司 | 2024-04-12 | — | — | CN | claimed |
| CN-117683114-A | Preparation method of thymalfasin | 江苏诺泰澳赛诺生物制药股份有限公司 | 2024-03-12 | — | — | CN | claimed |
| US-20240067694-A1 | SYNTHESIS OF TEDUGLUTIDE | BIOCON LIMITED (IN) | 2024-02-29 | — | — | US | claimed |
| US-20230295232-A1 | SOLUTION PHASE ROUTES FOR WNT HEXAPEPTIDES | WNTRESEARCH AB (SE) | 2023-09-21 | — | — | US | claimed |
| EP-3841107-B1 | SOLUTION PHASE ROUTES FOR WNT HEXAPEPTIDES | WNTRESEARCH AB (SE) | 2023-06-28 | — | — | EP | claimed |
| EP-4722229-A1 | ADAPTOR MOLECULES FOR TARGETED CELL IMMUNOTHERAPIES | Universität Zürich (CH) | 2026-04-08 | — | — | EP | disclosed |
| EP-4720072-A2 | RAS INHIBITORS | Revolution Medicines, Inc. (US) | 2026-04-08 | — | — | EP | disclosed |
| US-20260042795-A1 | DIPROPYLAMINE AS BASE FOR THE USE IN FMOC DEPROTECTION IN SOLID-PHASE PEPTIDE SYNTHESIS | Universität Bern (CH) | 2026-02-12 | — | — | US | disclosed |
| CN-120757472-A | Method suitable for industrial production of aspartic acid derivative | 成都市科隆化学品有限公司 | 2025-10-10 | — | — | CN | disclosed |
| EP-4611793-A1 | INSULIN DERIVATIVES | Ustav organicke chemie a biochemie Akademie ved CR, v.v.i. (CZ) | 2025-09-10 | — | — | EP | disclosed |
| EP-3972694-A1 | IMMUNOMODULATORS | Bristol-Myers Squibb Company (US) | 2022-03-30 | — | — | EP | disclosed |
| WO-2022050529-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | ㈜베르티스 | 2022-03-10 | — | — | WO | disclosed |
| WO-2022047517-A1 | DERIVATISATION OF PEPTIDES AND PROTEINS | FLOREY INSTITUTE FOR NEUROSCIENCE AND MENTAL HEALTH (AU) | 2022-03-10 | — | — | WO | disclosed |
| CN-114075274-A | Somarunotide analog and preparation method and application thereof | 浙江湃肽生物有限公司深圳分公司 | 2022-02-22 | — | — | CN | disclosed |
| CN-114014843-A | PSMA (patterned beam-selective membrane antigen) targeted nuclide/fluorescent bimodal ligand, molecular probe and application | 北京大学第一医院 | 2022-02-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260042795-A1 | DIPROPYLAMINE AS BASE FOR THE USE IN FMOC DEPROTECTION IN SOLID-PHASE PEPTIDE SYNTHESIS | PTMS, PEPD, ASNS | CASP3 4268/4885MDM4 538/4885TP53 2254/4885 |
| US-20240067694-A1 | SYNTHESIS OF TEDUGLUTIDE | DNPEP, GCLC, PTMS | CASP3 446/4885MDM4 2266/4885TP53 1584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.